{"id":55670,"date":"2026-01-28T13:32:15","date_gmt":"2026-01-28T05:32:15","guid":{"rendered":"https:\/\/flcube.com\/?p=55670"},"modified":"2026-01-28T13:32:15","modified_gmt":"2026-01-28T05:32:15","slug":"nanjing-leads-biolabs-secures-fda-fast-track-for-lbl-034-in-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55670","title":{"rendered":"Nanjing Leads Biolabs Secures FDA Fast Track for LBL-034 in Multiple Myeloma"},"content":{"rendered":"\n

Nanjing Leads Biolabs Co., Ltd.<\/strong> (HKG: 9887<\/a>)\u00a0announced that LBL-034<\/strong>, a GPRC5D\/CD3 bispecific antibody (BsAb)<\/strong> T\u2011cell engager, has been granted Fast Track Designation (FTD)<\/strong> by the U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of relapsed\/refractory multiple myeloma (RRMM)<\/strong>. This follows Orphan Drug Designation (ODD)<\/strong> received in October\u202f2024<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone & Clinical Context<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Nanjing Leads Biolabs Co., Ltd.<\/td><\/tr>
Drug<\/strong><\/td>LBL-034 (GPRC5D\/CD3 bispecific antibody)<\/td><\/tr>
Designation<\/strong><\/td>FDA Fast Track Designation (FTD)<\/td><\/tr>
Indication<\/strong><\/td>Relapsed\/refractory multiple myeloma (RRMM)<\/td><\/tr>
Mechanism<\/strong><\/td>T\u2011cell engager redirects and activates T cells to target GPRC5D\u2011positive cancer cells<\/td><\/tr>
Previous Designation<\/strong><\/td>Orphan Drug Designation (October\u202f2024)<\/td><\/tr>
Clinical Stage<\/strong><\/td>Phase\u202fI\/II trials underway<\/td><\/tr>
Key Advantages<\/strong><\/td>Lower T\u2011cell exhaustion, reduced cytokine release syndrome (CRS) and immunotoxicity risk<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Innovation<\/h2>\n\n\n\n